Dysfunction of the CNS-heart axis in mouse models of Huntington's disease.

Dysfunction of the CNS-heart axis in mouse models of Huntington's disease.

Cardiac remodelling and contractile dysfunction occur during both acute and chronic disease processes including the accumulation of insoluble aggregates of misfolded amyloid proteins that are typical features of Alzheimer's, Parkinson's and Huntington's disease (HD). While HD has been...

Full description

Bibliographic Details
Main Authors:	Michal Mielcarek, Linda Inuabasi, Marie K Bondulich, Thomas Muller, Georgina F Osborne, Sophie A Franklin, Donna L Smith, Andreas Neueder, Jim Rosinski, Ivan Rattray, Andrea Protti, Gillian P Bates
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-08-01
Series:	PLoS Genetics
Online Access:	http://europepmc.org/articles/PMC4125112?pdf=render

Similar Items

The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model.
by: Michal Mielcarek, et al.
Published: (2014-01-01)

SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.
by: Michal Mielcarek, et al.
Published: (2011-01-01)

Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease
by: Sathasivam, Kirupa, et al.
Published: (2013)

Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease
by: Sathasivam, Kirupa, et al.
Published: (2013)

Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington’s disease
by: Marie Katrin Bondulich, et al.
Published: (2021-03-01)

HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy.
by: Michal Mielcarek, et al.
Published: (2015-03-01)

HDAC4 does not act as a protein deacetylase in the postnatal murine brain in vivo.
by: Michal Mielcarek, et al.
Published: (2013-01-01)

Silencing Srsf6 does not modulate incomplete splicing of the huntingtin gene in Huntington’s disease models
by: Michael A. Mason, et al.
Published: (2020-08-01)

The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington’s disease patients
by: Andreas Neueder, et al.
Published: (2017-05-01)

HSF1-dependent and -independent regulation of the mammalian in vivo heat shock response and its impairment in Huntington's disease mouse models
by: Neueder, Andreas, et al.
Published: (2018)

Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington’s disease
by: El-Akabawy Gehan, et al.
Published: (2012-08-01)

Neuro-Cardio Mechanisms in Huntington’s Disease and Other Neurodegenerative Disorders
by: Bethan J. Critchley, et al.
Published: (2018-05-01)

A shared mechanism of muscle wasting in cancer and Huntington's disease
by: Michal Mielcarek, et al.
Published: (2015-12-01)

Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease.
by: Caroline L Benn, et al.
Published: (2009-06-01)

Skeletal muscle pathology in Huntington’s Disease.
by: Daniel eZielonka, et al.
Published: (2014-10-01)

Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease.
by: Ivan Rattray, et al.
Published: (2013-01-01)

Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the HdhQ150/Q150 Mouse Model of Huntington's Disease.
by: Ivan Rattray, et al.
Published: (2017-01-01)

The role of the ZEB1–neuroinflammation axis in CNS disorders
by: Elham Poonaki, et al.
Published: (2022-11-01)

Combining feature selection and shape analysis uncovers precise rules for miRNA regulation in Huntington’s disease mice
by: Lucile Mégret, et al.
Published: (2020-02-01)

SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington's Disease Mice.
by: Raffaella Tulino, et al.
Published: (2016-01-01)

HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration.
by: Michal Mielcarek, et al.
Published: (2013-11-01)

Correction: SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington's Disease Mice.
by: Raffaella Tulino, et al.
Published: (2016-01-01)

Deregulated Transcriptome as a Platform for Adrenal Huntington’s Disease-Related Pathology
by: Anna Olechnowicz, et al.
Published: (2024-02-01)

Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction
by: Ruben Smith, et al.
Published: (2005-12-01)

Prevalence of Non-psychiatric Comorbidities in Pre-symptomatic and Symptomatic Huntington's Disease Gene Carriers in Poland
by: Daniel Zielonka, et al.
Published: (2020-03-01)

Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease
by: Bates Gillian P, et al.
Published: (2008-10-01)

The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease.
by: John S Bett, et al.
Published: (2009-01-01)

Regulatory mechanisms of incomplete huntingtin mRNA splicing
by: Andreas Neueder, et al.
Published: (2018-09-01)

SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo.
by: Anna Bobrowska, et al.
Published: (2012-01-01)

Correction: SIRT2 Ablation Has No Effect on Tubulin Acetylation in Brain, Cholesterol Biosynthesis or the Progression of Huntington’s Disease Phenotypes In Vivo
by: Bobrowska, Anna, et al.
Published: (2022)

Correction: SIRT2 Ablation Has No Effect on Tubulin Acetylation in Brain, Cholesterol Biosynthesis or the Progression of Huntington's Disease Phenotypes In Vivo.
by: Anna Bobrowska, et al.
Published: (2021-01-01)

Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.
by: Lara Moumné, et al.
Published: (2012-01-01)

Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease.
by: Anna Bobrowska, et al.
Published: (2011-01-01)

Effects on the Hypothalamo-Pituitary Axis in Patients with CNS or Head and Neck Tumors following Radiotherapy
by: Jordan Bouter, et al.
Published: (2023-07-01)

A PML/Slit Axis Controls Physiological Cell Migration and Cancer Invasion in the CNS
by: Valeria Amodeo, et al.
Published: (2017-07-01)

Proteasomal dysfunction in aging and Huntington disease
by: Xiao-Jiang Li, et al.
Published: (2011-07-01)

SIRT2 Ablation Has No Effect on Tubulin Acetylation in Brain, Cholesterol Biosynthesis or the Progression of Huntington's Disease Phenotypes In Vivo
by: Bobrowska, Anna, et al.
Published: (2012)

PACAP/GCGa Is an Important Modulator of the Amphioxus CNS-Hatschek’s Pit Axis, the Homolog of the Vertebrate Hypothalamic-Pituitary Axis in the Basal Chordates
by: Jason S. W. On, et al.
Published: (2022-04-01)

Convulsant bicuculline modifies CNS muscarinic receptor affinity
by: Rodríguez de Lores Arnaiz Georgina, et al.
Published: (2006-04-01)

Possible contribution of CNS inflammation to the pathogenesis of prion disease
by: Franklin, S, et al.
Published: (2006)